Matthew Goetz, M.D., professor of oncology at the Mayo Clinic where he is also co-leader of the Women's Cancer Program and chair of the Breast Cancer Disease-Oriented Group, discusses the research he presented at the 2018 San Antonio Breast Cancer Symposium on patient-reported outcomes from women being treated with Verzenio (chemical name: abemaciclib) plus an aromatase inhibitor as the first treatment for advanced-stage, hormone-receptor-positive, HER2-negative breast cancer. Listen to the podcast to hear Dr. Goetz talk about: what patient-reported outcomes are and why they're important for both doctors and patients the Verzenio side effects reported in the study how diarrhea caused by Verzenio can be proactively managed so a woman doesn't have to plan her life around a side effect

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related